ArticleFrontiers in pharmacology2025
Electrochemical simulation of psychotropic drug metabolism compared to
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrochemical Simulation of 25B-NBOMe Phase I Metabolism and Metabolite Profiling by HPLC-QTOF-MS.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Psychotropic drugs strongly affect the human psyche through their ability to modulate the neurotransmitter activity and to treat mental disorders and diseases. Monitoring of psychotropic drugs in clinical studies is significant. Thus. establishing methodologies for analyzing these drugs and their pharmacologically active metabolites in biological matrices is essential for patients' safety. Therefore, therapeutic drug monitoring (TDM) of these drugs in patients receiving pharmacotherapy in psychiatric hospitals is necessary to avoid medical complications, psychiatric adverse effects, or poisoning. In addition to TDM, the main factor in pharmacokinetics that should be monitored along with the drug is its metabolic pathway. The literature on transformation products (TPs) resulting from the psychotropic drug degradation is limited. Hence, to investigate the potential TPs of target compounds, electrochemistry (EC) and liver microsome assays were used to generate TPs, which were further characterized using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The results obtained by EC-(LC)-MS and liver microsome assays were compared with conventional Methods: The electrochemical mimicry of the oxidative phase I and II metabolism was achieved in a thin-layer cell equipped with a boron-doped diamond (BDD) working electrode under controlled potential conditions. Structures were proposed for the electrochemically generated products based on the MS/MS experiments. Moreover, in order to examine the proposed metabolic pathways of target compounds, the incubation with human liver microsomes was applied. Additionally, a sensitive, specific, and rapid LC-MS/MS method was developed and validated to quantify selected drugs and their metabolites in biological samples. The preparation of biological samples was accomplished through microextraction by a packed sorbent (MEPS). Finally, the results from LC-MS/MS analysis of biological samples, liver microsomes and electrochemical TPs were compared to evaluate the quality of electrochemical metabolism mimicry. Results and discussion: Data from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.